Use of Bedaquiline as A Novel Antitubercular Agent in Patient with Multidrug- Resistant Tuberculosis -A Review

Author: Rajveer Singh, Ranjeet Kumar, Sonalal Prasad Kushwaha

Bedaquiline use as first novel drug which has been approved by the US Food and Drug Administration (FDA) in December 2012 for the treastment of MDR-TB. Bedaquiline is a type of novel reserved antitubercular drug belongs to diarylquinoline class. Bedaquiline acts on Mycobacterium tuberculosis, which is efficacious in rifampin,Isoniazidas well as other antituberculardrugsresistant by directly inhibiting ATP synthase enzyme. The aim of the study is to review the efficacy of bedaquilinein multidrug-resistant tuberculosis. A website based latest research which has been done by screening of different reputed research article journals, conference and review articles related to the use of bedaquiline in multidrug-resistant tuberculosis. In multidrug-resistant tuberculosis, bedaquiline is the most effectiveantituberculardrug as compare to other second line anti-mycobacterial agents. After reviewing the different article based on efficacy of bedaquiline, this drug is more efficacious in the patients with MDR-TB and it could improve the quality of life in MDR-TB patients.

Download PDF